Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517647 · ClinicalTrials.gov registry record · Phase 4
Atomoxetine Pilot Study in Preschool Children With ADHD
A Phase 4 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT00517647 is a Phase 4 study that has completed, run by University of Arizona. The registered enrollment target is 31 participants.
The verdict
NCT00517647, a Phase 4 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if atomoxetine (a common brand name is Strattera), a medicine that is used for treating older children with Attention Deficit and Hyperactivity Disorder (ADHD), is also safe and helpful for ADHD problems in young children. While atomoxetine is not approved by the FDA for use in children younger than 6 years, the FDA has given permission to study this drug in this age group.
Interventions
- DRUG ATMX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2004-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517647
The ClinicalTrials.gov registry entry for NCT00517647 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATMX is the first listed.
NCT00517647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00517647 about?
NCT00517647 is a clinical study titled "Atomoxetine Pilot Study in Preschool Children With ADHD". The purpose of this study is to determine if atomoxetine (a common brand name is Strattera), a medicine that is used for treating older children with Attention Deficit and Hyperactivity Disorder (ADHD), is also safe and helpful for ADHD problems in young children. While atomoxetine is not approved b...
What is the current status of trial NCT00517647?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2004-04.
What interventions are being tested in trial NCT00517647?
The interventions under investigation include: ATMX (DRUG).
Who is sponsoring clinical trial NCT00517647?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.